

:

Company name Exodus Technology Ltd. \* Website [www.nano-pk.com](http://www.nano-pk.com) \*

CEO name Michael Zilbershlag \*

Select a CATEGORY: Biotech/Pharma or Medical Devices or Bio Convergence \*

(Delete categories you are not selecting)

Select one SESSION per abstract from the list below \*

(Delete sessions you are not selecting)

**“Beyond Neuropharma and Neurotech: Integrated Brain Control.”**

- Executive Summary / Investment Rational: Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Exodus's US-FPA technology uses gold nanoparticles and retrograde tracers to permanently ablate pain-signalling DRG neurons via ultrasound. Targeting an \$81B market, the company completed successful controlled preclinical trials. Founders are Harvard medical device veterans, We raised \$1M to date and are seeking \$3M in equity for Phase I/II trials.

- Core Technology: What is the technology, its uniqueness, and its value proposition?

Exodus's "US-FPA technology" conjugates gold nanoparticles with retrograde tracers to target sensory neuron bodies in the Dorsal Root Ganglion. Its uniqueness lies in utilizing natural axonal transport for selective and permanent ablation of pain-signaling neurons while fully preserving motor function. This provides a minimally invasive, non-addictive alternative to chronic medication or surgery.

- Product Profile/Pipeline: Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Following successful preclinical trials, the company is planning First-In-Man (FIM) Phase I/II trials with 20 patients. Targeting an \$20B market (\$6.7B knee OA; \$8B lower back pain), potential collaborations include \*RF ablation vendors\*\* and \*\*pain-management pharma\*\* companies.

- Business Strategy: Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

generates short-term revenue by selling solution vials to clinics without dedicated reimbursement codes, leveraging existing billing practices. Long-term, the company will adopt reimbursement codes similar to **RF ablation** while securing a separate pharmaceutical code for its proprietary solution. This strategy supports the company's roadmap toward **full commercialization and over-billion dollar valuation**

- What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

Exodus is transitioning from its successful preclinical foundation to Stage 2 (2026–2027), focusing on GLP-compliant preclinical work and First-In-Man (FIM) Phase I/II trials in Eastern Europe. Organizationally, the company plans to cooperate with RF ablation device vendors to leverage existing clinical infrastructures. Financially, it is raising \$12M (\$3M equity) by the end of 2026, with preparations for U.S. Phase IIb/III studies.

